Efficacy and Safety in Retinal Vein Occlusion Treated with at Least Three Consecutive Intravitreal Dexamethasone Implants

Table 1

Mean (±SE) LogMar visual acuity before and after 3 consecutive injections of dexamethasone, overall and according to the occlusion type and previous therapy.

	Baseline	2 months after 3rd injection	Mean change (95% CI)
Overall ()	0.74 (0.08)	0.45 (0.04)	−0.30 (−0.50 to −0.08)	0.009
Occlusion type
CRVO ()	0.81 (0.14)	0.46 (0.05)	−0.35 (−0.70 to −0.002)	0.049	0.56
BRVO ()	0.66 (0.04)	0.43 (0.10)	−0.23 (−0.46 to −0.004)	0.047
Treatment-naïve eyes
No ()	0.71 (0.10)	0.44 (0.06)	−0.28 (−0.56 to 0.004)	0.053	0.80
Yes ()	0.80 (0.15)	0.47 (0.08)	−0.39 (−0.77 to −0.001)	0.049

CRVO: central retinal vein occlusion branch; BRVO: branch retinal vein occlusion branch.
Linear mixed regression analysis was used to estimate the mean change and to perform the between comparison.
Defined as first LogMar values before 1st injection of dexamethasone.
for comparison between baseline and postinjection values.
for between-group comparison calculated by including interaction term between groups and time of measure in linear mixed model.